A randomized dose-escalation study on the safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of a novel recombinant human albumin in healthy subjects

医学 耐受性 药效学 药代动力学 安慰剂 药理学 免疫原性 内科学 不利影响 胃肠病学 白蛋白 免疫学 抗体 病理 替代医学
作者
Cuiyun Li,Wei Xiang,Min Wu,Hong Zhang,Jianqiu Cheng,Tao Yang,Jiajia Mai,Xiumei Chi,Xiuzhu Gao,Yanhua Ding,Junqi Niu
出处
期刊:European Journal of Pharmaceutical Sciences [Elsevier BV]
卷期号:165: 105923-105923 被引量:5
标识
DOI:10.1016/j.ejps.2021.105923
摘要

Recombinant human albumin (rHA) is an alternative to human serum albumin (HSA) for treating ascites in cirrhosis patients. This study was to evaluate the safety, tolerability, immunogenicity, and pharmacokinetics/pharmacodynamics (PK/PD) of rHA in healthy subjects to guide the design for further clinical trials. Healthy subjects aged 18–55 years were enrolled in this double-blinded, first-in-human, placebo-controlled single ascending dose (SAD) (1.25, 5, 10, 20, or 30g) and positive-controlled multiple-dose study (3-day treatment of 10g/day for three cycles every three weeks). The safety was assessed by adverse events (AEs). Antibodies (IgE and IgD) and cytokines were analyzed for immunogenicity. Serum albumin levels and changes in plasma colloid osmotic pressure (PCOP) and hematocrit (HCT) were measured for PK/PD analysis. rHA was well tolerated as all AEs were assessed as mild or moderate. No severe allergy or difference in the incidence of AEs was observed among the different cohorts in the SAD study or in the different cycles in the multiple-dose study. The incidence of AEs was similar for the rHA and HSA cohort. Antibodies or cytokines showed no changes after drug administration. As expected, serum albumin levels and PCOP increases, and HCT ratio decreases were dose-related with significant differences (p < 0.01). No differences were observed between rHA and HSA. rHA is safe and well-tolerated in healthy Chinese subjects. rHA and HSA exhibited similar safety, tolerability, and PK/PD profiles. The results support further evaluation of rHA treatment in cirrhotic patients with ascites. The clinical trial registration numbers are CTR20191221 (http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
苗条的一一完成签到,获得积分10
1秒前
安详的囧发布了新的文献求助10
1秒前
ccalvintan发布了新的文献求助10
2秒前
2秒前
3秒前
MchemG应助闲听松风眠采纳,获得10
3秒前
3秒前
3秒前
3秒前
NexusExplorer应助灵巧鑫采纳,获得30
4秒前
4秒前
共享精神应助鲤跃采纳,获得10
5秒前
SYLH应助橙子采纳,获得20
5秒前
特安谭完成签到,获得积分10
5秒前
6秒前
RoKing完成签到,获得积分10
6秒前
ding完成签到,获得积分10
7秒前
胡志飞发布了新的文献求助10
7秒前
科研通AI2S应助嗷嗷采纳,获得10
7秒前
zzz发布了新的文献求助10
8秒前
深情安青应助好宝宝采纳,获得10
8秒前
8秒前
8秒前
8秒前
9秒前
Noah完成签到 ,获得积分10
9秒前
SciGPT应助大冰采纳,获得10
9秒前
量子星尘发布了新的文献求助80
9秒前
天边发布了新的文献求助10
10秒前
未央歌完成签到 ,获得积分10
10秒前
10秒前
Xinger完成签到,获得积分10
11秒前
12秒前
sssaw发布了新的文献求助10
12秒前
RoKing发布了新的文献求助10
13秒前
香蕉觅云应助zy采纳,获得10
13秒前
Xinger发布了新的文献求助10
14秒前
xiaozhiok发布了新的文献求助10
14秒前
思垢发布了新的文献求助10
14秒前
15秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988732
求助须知:如何正确求助?哪些是违规求助? 3531027
关于积分的说明 11252281
捐赠科研通 3269732
什么是DOI,文献DOI怎么找? 1804764
邀请新用户注册赠送积分活动 881869
科研通“疑难数据库(出版商)”最低求助积分说明 809021